TAS-102 Monotherapy and Combination Therapy with Bevacizumab for Metastatic Colorectal Cancer

Table 1

Characteristics of included studies.

Study	Age (years)	Sex (male/female)	ECOG performance status (0/≥1)	KRAS status (wild/mutated)	Methods	Sample	mOS (months)	mPFS (months)
Mayer et al. 2015 [4]	63 (27-82)	326/208	301/233	272/262	TAS-102	534	7.1 (6.5-7.8)	2 (1.9-2.1)
	63 (27-82)	165/101	147/119	131/135	Placebo	266	5.3 (4.6-6.0)	1.7 (1.7-1.8)
Pfeiffer et al. 2020 [15]	64 (57-69)	24/22	23/23	19/27	TAS-102+B	46	NA	4.6 (3.5-6.5)
	67 (58-72)	30/17	15/32	18/29	TAS-102	47	NA	2.6 (1.6-3.5)
Sueda et al. 2016 [16]	66 (44-80)	10/4	1/13	9/5	TAS-102	14	6.3 (3.21-9.93)	1 (0.92-6.39)
	59 (37-83)	12/11	10/13	12/11	REG	23	5.8 (3.7-11.7)	0 (1.64-4.52)
Masuishi et al. 2017 [17]	NA	30/24	NA	21/32	TAS-102	54	6.5 (5.3-8.3)	2.1 (1.8-3.1)
	NA	90/56	NA	78/67	REG	146	6.7 (5.8-7.6)	2.1 (1.8-2.5)
Makiyama et al. 2018 [18]	66 (39-82)	6/5	5/6	NA	TAS-102+B	11	Not reached	5.8
	69 (47-82)	20/13	11/22	NA	TAS-102	33	6.4	1.8
Yoshino et al. 2012 [5]	63 (28-80)	64/48	72/40	54/45	TAS-102	112	9.0 (7.3-11.3)	NA
	62 (39-79)	28/29	35/22	24/26	Placebo	57	6.6 (4.9-8.0)	NA
Cutsem et al. 2017 [9]	60.2 (11.86)	31/33	28/36	35/29	TAS-102	64	6.5	NA
	58.5 (11.02)	18/17	13/22	17/18	Placebo	35	4.3	NA
	61.8 (9.98)	167/104	138/133	123/148	TAS-102	271	NA	NA
	62.1 (10.42)	82/50	68/64	68/64	Placebo	132	NA	NA
	61.9 (10.09)	113/65	128/50	94/84	TAS-102	178	7.8	NA
	62.1 (10.40)	58/30	60/28	40/48	Placebo	88	6.7	NA
Xu et al. 2017 [10]	58 (26-81)	170/101	64/207	172/99	TAS-102	271	7.8 (7.1-8.8)	NA
	56 (24-80)	84/51	30/105	85/50	Placebo	135	7.1 (5.9-8.2)	NA
Longo-Muñoz et al. 2016 [19]	5 (27-81)	48/32	24/56	35/45	TAS-102	80	6.8	2
	5 (39-78)	21/11	11/21	17/15	Placebo	32	4.6	1.7
Moriwaki et al. 2018 [20]	64 (29-86)	197/130	128/199	160/161	TAS-102	327	7.4 (6.6-8.3)	NA
	64 (31-84)	126/97	95/128	88/109	REG	223	7.9 (6.8-9.2)	NA
Kotani et al. 2019 [21]	60 (23-79)	35/25	35/25	28/32	TAS-102+B	60	8.6 (6.9-10.3)	3.7 (2.3-5.1)
	65 (30-80)	42/24	42/24	30/36	TAS-102	66	8.0 (6.7-9.4)	2.2 (1.8-2.6)
Fujii et al. 2020 [11]	67 (50-74)	13/8	NA	10/11	TAS-102+B	21	14.4 (7.9-NA)	NA
	67.5 (59.8-71.2)	16/20	NA	16/20	TAS-102	36	4.5 (3.2-6.5)	NA
Ogata et al. 2020 [22]	68 (40-85)	38/39	35/42	53/24	TAS-102	77	11.4	3.3
	66 (41-81)	30/27	30/27	36/21	REG	57	9.9	2
Nose et al. 2020 [23]	73 (49-90)	16/16	12/20	14/17	TAS-102+B	32	11.7	4.7
	70.5 (43-88)	15/9	7/17	14/10	TAS-102	24	6.3	1.8
Cicero et al. 2020 [24]	78 (70-86)	28/22	18/32	18/22	TAS-102	50	6.7 (5.7-11.3)	2.1 (1.2-3.2)
Cecchini et al. 2021 [25]	NA	NA	NA	NA	TAS-102	41	6.8 (5.7-10)	2.7 (2.4-4.8)
Sforza et al. 2017 [26]	65 (48-82)	31/12	27/16	16/27	TAS-102	43	6.6 (2.8-10.4)	2.8 (2.5-3.1)
Montes et al. 2020 [27]	63 (37-83)	108/52	18/142	57/103	TAS-102	160	7.64 (6.15-9.13)	2.75 (2.57-2.94)
Takahashi et al. 2021 [28]	73 (65-81)	21/9	NA	NA	TAS-102	30	5.7 (3.7-8.9)	2.3 (1.9-4.3)
Kwakman et al. 2018 [29]	62 (30-88)	92/44	46/90	53/83	TAS-102	136	5.4 (4.0-6.9)	2.1 (1.8-2.3)
Moehler et al. 2021 [30]	60 (35-78)	6/6	6/6	NA	TAS-102	12	11.1 (2.3-18.2)	3.81 (1.51-5.29)
Yoshida et al. 2020 [31]	67 (45-78)	20/12	23/9	14/18	TAS-102+B	32	9.2 (5.5-12.8)	4.5 (1.8-7.1)
Wallander et al. 2020 [32]	65 (38-78)	28/20	13/34	17/29	TAS-102	48	6.4 (4.4-8.4)	2.3 (1.8-2.7)
Satake et al. 2020 [33]	69 (33-82)	24/20	25/19	25/19	TAS-102+B	44	10.86 (8.32-13.68)	4.29 (2.54-5.83)
Carries et al. 2019 [34]	65.29 (40-88)	49/35	13/71	31/53	TAS-102	84	8.3 (6.23-9.87)	2.62 (2.32-3.05)